Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 14 Carcinoma, Non-Small-Cell Lung 11 Lung Neoplasms 9 Pancreatic Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Head and Neck Neoplasms 7 Colorectal Neoplasms 7 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Carcinoma, Hepatocellular 6 Triple Negative Breast Neoplasms 5 Urinary Bladder Neoplasms 4 Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Biliary Tract Neoplasms 4 Stomach Neoplasms 3 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Lymphoma, Follicular 3 Kidney Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Squamous Cell 3 Carcinoma, Renal Cell 3 Carcinoma 3 Adenocarcinoma Of Esophagus 3 Uterine Cervical Neoplasms 2 Recurrence 2 Oropharyngeal Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Lymphoma, T-Cell, Cutaneous 2

Interventions

Temozolomide 69 Radiotherapy 30 Bevacizumab 24 Carboplatin 13 pembrolizumab 12 Radiation 11 Carmustine 8 Irinotecan 7 temsirolimus 6 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 atezolizumab 5 Vorinostat 5 Sirolimus 5 Radiotherapy, Intensity-Modulated 5 Nivolumab 5 Lomustine 5 Everolimus 5 fludarabine 4 Radiotherapy, Conformal 4 Magnetic Resonance Spectroscopy 4 Cyclophosphamide 4 Aminolevulinic Acid 4 tipifarnib 3 Sorafenib 3 Paclitaxel 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × durvalumab × Clear all

NCT02866747 2026-04-14

STERIMGLI

Institut Claudius Regaud

Phase 1/2 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡